Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …

Carbapenem-resistant Acinetobacter baumannii (CRAB) causes colonization and infection
predominantly in hospitalized patients. Distinction between the two is a challenge. When …

Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter
baumannii (CRAB) infections, but clinical data are limited. This is an observational …

Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

Scope These ESCMID guidelines address the targeted antibiotic treatment of third-
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …

Management of patients with infections caused by multidrug-resistant organisms is
challenging and requires a multidisciplinary approach to achieve successful clinical …

The polymyxin and lipopeptide classes of antibiotics are membrane-targeting drugs of last
resort used to treat infections caused by multi-drug-resistant pathogens. Despite similar …

Antimicrobial drug resistance is one of the major threats to global health. It has made
common infections increasingly difficult or impossible to treat, and leads to higher medical …

With the current crisis related to the emergence of carbapenem-resistant Gram-negative
bacteria (CR-GNB), classical treatment approaches with so-called “old-fashion antibiotics” …

Acinetobacter baumannii is a Gram-negative, multidrug-resistant (MDR) pathogen that
causes nosocomial infections, especially in intensive care units (ICUs) and …